$12.15
+0.04 (+0.33%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RDY is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 9 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, MILLENNIUM MANAGEMENT LLC, Man Group plc, +4 more) · FINRA short interest 6.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common WartsNCT02798419The proportion of subjects categorized as treatment responders (defined as having at least 91% reduction in surface area, averaged across all target warts)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: DFD05 Cream, Active01 Cream | Common Warts | 50 | May 2016actual | 2016-08-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19